%0 Journal Article
%T The use of a pill containing ethinylestradiol-norgestimate improves female sexuality despite the decrease in circulating androgens: a pilot study.
%A Guida M
%A Quercitelli L
%A De Franciscis P
%A Fiorenza M
%A Sgandurra A
%A La Marca A
%A Grandi G
%J Eur J Contracept Reprod Health Care
%V 0
%N 0
%D 2024 Jun 28
%M 38940613
%F 1.752
%R 10.1080/13625187.2024.2369833
%X <B>UNASSIGNED: </B>To evaluate the initial impact of a combined oral contraceptive (COC) containing norgestimate (NGM) on female sexuality and on circulating androgen levels in users.<BR><B>UNASSIGNED: </B>Six months modification in the McCoy Female Sexuality Questionnaire (MFSQ) and testosterone (T) and dehydroepiandrosterone sulphate (DHEAS) serum levels in women starting a monophasic pill containing ethinyl-estradiol (EE) 35 µg and NGM 0.250 mg.<BR><B>UNASSIGNED: </B>The study was completed by 36 subjects. There was a significant increase in MFSQ during treatment (p < 0.0001) (and its domains with the exclusion of vaginal lubrication domain) with concomitant decreases in T (-4.45%, p < 0.0001) and DHEAS (-19.41%, p < 0.0001) serum levels.<BR><B>UNASSIGNED: </B>Contraception with EE/NGM was associated with a short term non-deteriorating effect on sexuality despite the evident decrease in androgen levels. Female sexuality during COC use is a complex topic and is not only linked with changes in serum androgen levels.<BR>EE/NGM treatment has a short term non-deteriorating effect on sexuality despite the evident decrease in androgen serum levels.